☆ 4.4 Article

Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Get Full Text
Add to Collection

Journal

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
Volume 71, Issue 8, Pages 285-289

Publisher

Centers for Disease Control MMWR Office
DOI: 10.15585/mmwr.mm7108a1

Keywords

-

Categories

Public, Environmental & Occupational Health

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.